Payment overview · 2025
General Payments
$30.60
2 reported records · 2 companies
Healthcare provider profile · identity verified
Renie Jordon, M. D.
Allopathic & Osteopathic Physicians|Internal Medicine · MCCOMB, MS · NPI 1962451294
Verified facts
What the public records show
CMS Open Payments records show Renie Jordon, M. D. received $30.60 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 51.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Symbicort by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.86 | 51.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.74 | 48.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $30.60 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 836 | 202 |
| Atorvastatin Calcium | Atorvastatin Calcium | 516 | 144 |
| Hydrochlorothiazide | Hydrochlorothiazide | 416 | 101 |
| Metformin Hcl | Metformin Hcl | 414 | 111 |
| Furosemide | Furosemide | 413 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 411 | 89 |
| Gabapentin | Gabapentin | 357 | 90 |
| Potassium Chloride | Potassium Chloride | 297 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 275 | 65 |
| Lisinopril | Lisinopril | 265 | 67 |
| Diclofenac Sodium | Diclofenac Sodium | 243 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 54 |
| Carvedilol | Carvedilol | 221 | 53 |
| Losartan Potassium | Losartan Potassium | 221 | 64 |
| Meloxicam | Meloxicam | 211 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 50 |
| Omeprazole | Omeprazole | 196 | 45 |
| Eliquis | Apixaban | 181 | 33 |
| Sertraline Hcl | Sertraline Hcl | 173 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 41 |
| Simvastatin | Simvastatin | 165 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 49 |
| Glimepiride | Glimepiride | 142 | 38 |
| Lovastatin | Lovastatin | 130 | 25 |
| Clonidine Hcl | Clonidine Hcl | 129 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 22 |
| Trazodone Hcl | Trazodone Hcl | 106 | 24 |
| Torsemide | Torsemide | 102 | 29 |
| Januvia | Sitagliptin Phosphate | 100 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 97 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 22 |
| Allopurinol | Allopurinol | 83 | 26 |
| Ibuprofen | Ibuprofen | 80 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 14 |
| Jardiance | Empagliflozin | 78 | 21 |
| Nifedipine Er | Nifedipine | 78 | 18 |
| Colchicine | Colchicine | 77 | 17 |
| Buspirone Hcl | Buspirone Hcl | 75 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 74 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 28 |
| Glipizide | Glipizide | 73 | 18 |
| Atenolol | Atenolol | 70 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 17 |
| Naproxen | Naproxen | 66 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 13 |
| Donepezil Hcl | Donepezil Hcl | 60 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 15 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 59 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 46 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 13 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 55 | suppressed |
| Alprazolam | Alprazolam | 54 | suppressed |
| Spironolactone | Spironolactone | 54 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 18 |
| Meclizine Hcl | Meclizine Hcl | 52 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 12 |
| Famotidine | Famotidine | 51 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 12 |
| Labetalol Hcl | Labetalol Hcl | 48 | 12 |
| Felodipine Er | Felodipine | 46 | 11 |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Lorazepam | Lorazepam | 43 | 12 |
| Metolazone | Metolazone | 43 | 17 |
| Prednisone | Prednisone | 42 | 27 |
| Ramipril | Ramipril | 40 | suppressed |
| Dexamethasone | Dexamethasone | 38 | 34 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | 11 |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 23 |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Cilostazol | Cilostazol | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 13 |
| Linzess | Linaclotide | 32 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Mitigare | Colchicine | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 20 |
| Temazepam | Temazepam | 27 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Bumetanide | Bumetanide | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Indomethacin | Indomethacin | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Propylthiouracil | Propylthiouracil | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Teriflunomide | Teriflunomide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30.60 · 2 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, VYEPTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error